LYELL IMMUNOPHARMA INC (LYEL)
US55083R1041 - Common Stock
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company...
LYEL Stock Earnings: Lyell Immunopharma Beats EPS for Q1 2024
LYEL stock results show that Lyell Immunopharma beat analyst estimates for earnings per share the first quarter of 2024.
LYEL Stock Earnings: Lyell Immunopharma Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lyell Immunopharma (NASDAQ:LYEL) just reported results for the first quarter of...
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarterOn...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Friday is here and we're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers this morning!
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company...
Lyell Immunopharma files $400M mixed securities shelf (NASDAQ:LYEL)
Lyell Immunopharma files preliminary prospectus to offer and sell up to $400M mixed securities shelf. Not an offer to sell.
Lyell Immunopharma reports Q4 results (NASDAQ:LYEL)
Lyell Immunopharma reports a Q4 net loss of $52.9M with revenue of approximately zero for the fourth quarter and year ended December 31, 2023.
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
On track to report initial clinical and translational data from lead CAR T-cell and TIL product candidates in 2024Received Orphan Drug Designation for...
Commit To Buy Lyell Immunopharma At $2.50, Earn 57.3% Annualized Using Options
Lyell Immunopharma Announces Participation in March Investor Conferences
Lyell Immunopharma Announces Participation in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company...
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company...
Lyell gets FDA orphan drug designation for melanoma drug (LYEL)
Lyell Immunopharma (LYEL) has been granted orphan drug designation for LYL845, which is in Phase 1 testing for advanced melanoma. Read more here.
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company...
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T‑cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today reported financial results and business highlights for the third quarter ended September 30, 2023.
Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing
Six presentations highlight innovations designed to shorten TIL manufacturing, new nonclinical data on LYL119, new technologies and clinical trials in progress
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten TIL manufacturing and clinical trials in progress
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten TIL manufacturing and clinical...
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform
/PRNewswire/ -- Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy...
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
Proof-of-concept manufacturing to be provided by Cellares for a key Lyell CAR T-cell therapy using Cellares' exclusive Cell ShuttleCollaboration to...